Atrium Therapeutics RNA 深 滬
已收盤 05-15 16:00:00 美东时间
13.23
-0.040
-0.30%
華盛通- 最 高13.97
- 今 開13.48
- 成交量 23.44万股
- 最 低 13.035
- 昨 收 13.27
- 總市值 2.05亿
- 52周最高 73.06
- 市盈率 靜 --
- 換手率 1.51%
- 52周最低 11.95
- 委 比 -20.85%
- 總股本 1551.50万
- 歷史最高 73.06
- 量 比 1.78
- 振 幅 7.05%
- 歷史最低 4.825
- 每 手 1
- 風險率 22.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25
Leerink Partners analyst Joseph Schwartz initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Outperform rating and announces Price Target of $25.
05-16 01:34
Atrium Therapeutics Q1净亏损1660万美元，BMS里程碑付款支撑收入
核心财务数据 Atrium Therapeutics公布2026年第一季度财报。公司报告期内净亏损为1663万美元，合每股亏损0.97美元。作为对比，公...
05-15 23:41
财报速睇 | Atrium Therapeutics 2026财年Q1营收0.20亿美元，同比增长900.0%；归母净利润亏损0.17亿美元，同比亏损扩大142.9%
华盛资讯5月15日讯，Atrium Therapeutics公布2026财年Q1业绩，公司Q1营收0.20亿美元，同比增长900.0%，归母净利润亏损0.17亿美元，同比亏损扩大142.9%。
05-15 07:32
Atrium Therapeutics Q1 EPS $(0.97) Beats $(1.10) Estimate, Sales $19.635M Beat $2.000M Estimate
Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.10) by 11.82 percent. This is a 7.78 percent decrease over losses of $(0.90) per share from
05-15 04:47
HC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics
HC Wainwright & Co. suspends Neutral rating on Atrium Therapeutics (NASDAQ:RNA).
05-01 19:11
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month
Oversold stocks in health care sector present buying opportunity. RSI compares stock's strength on up/down days & predicts short-term performance. Top oversold stocks: KNSA (28) NNOX (28.2) RNA (28.4).
04-21 18:26
Atrium Therapeutics grants inducement equity awards to seven new hires under Nasdaq rule
Atrium Therapeutics grants inducement equity awards to seven new hires under Nasdaq rule Atrium Therapeutics granted inducement equity awards to seven newly hired non-executive employees under its 2026 Employment Inducement Incentive Award Plan. Grants total 101,250 non-qualified stock options with
04-21 11:05
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Empl...
04-21 10:46
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Wells Fargo Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25
Wells Fargo analyst Yanan Zhu initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Overweight rating and announces Price Target of $25.
03-11 21:31
